The startup develops RNA-targeted gene medicines that utilize a platform for engineering bi-functional drugs, combining peptide-based cellular magnets with oligonucleotide therapeutics to enhance tissue uptake and specificity. This approach addresses the limitations of existing gene therapies by improving safety, efficacy, and cost-effective manufacturing for a wide range of human diseases.
Funding
$11.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current gene therapies face challenges in targeted delivery and efficient uptake by specific tissues, leading to potential off-target effects and limited therapeutic efficacy. Manufacturing complexities and high costs further restrict the accessibility and widespread application of these treatments.
Solution
The startup is developing RNA-targeted gene medicines using a platform that engineers bi-functional drugs. This platform combines peptide-based cellular magnets with oligonucleotide therapeutics to enhance tissue uptake and specificity. By improving targeted delivery, the technology aims to minimize off-target effects and increase the therapeutic impact of gene therapies. The approach also seeks to address manufacturing challenges, potentially leading to more cost-effective production and broader availability of gene-based treatments for various diseases.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing gene therapies for a wide range of human diseases.
Features
- Bi-functional drug design combining peptide-based cellular magnets and oligonucleotide therapeutics
- Enhanced tissue uptake and specificity for targeted delivery of gene medicines
- RNA-targeted approach for precise modulation of gene expression
- Potential for improved safety profiles compared to traditional gene therapies
- Streamlined manufacturing processes for cost-effective production